Compare Novartis AG (NVS) vs Western Alliance Bancorporation (WAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Western Alliance Bancorporation — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while Western Alliance Bancorporation trades at $79.8 (market cap $8.84B). The key difference: Novartis AG is far larger — about 32.8× Western Alliance Bancorporation's market cap, and Novartis AG pays the higher dividend (3.17%). Which is the better fit depends on your goals.
| NVS | WAL | |
|---|---|---|
Market Cap | $290.25B | $8.84B |
Sector | Health | Financials |
52-Week High | $168.62 | $96.08 |
52-Week Low | $113.50 | $66.70 |
Enterprise Value | $330.27B | — |
Dividend Yield | 3.17% | 2.07% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →
